A0 vs A1: The NIH Resubmission Decision Most PIs Get Wrong

Why This Decision Matters More Than Revision Tactics

Most grant-writing advice focuses on how to respond to reviewer critiques. That's not a bad place to focus, but it presupposes that a resubmission is the right move. Often it is. Sometimes it isn't — and submitting an A1 when a new A0 would have served you better is a mistake that takes at least two full review cycles to recover from.

A poorly timed A1 creates a paper trail. The Introduction page commits you to engaging with the prior summary statement, and reviewers arrive expecting to see those critiques addressed. If the core weaknesses were structural — the hypothesis was incremental, the question had been mostly answered elsewhere, or the framing didn't fit the institute's current priorities — a revision may not reach far enough. You can polish every sentence and still not move the score because the critique was never really about execution.

Conversely, abandoning a scored A0 for a fresh start when your critiques are specific and correctable means giving up the goodwill of assigned reviewers who already understand your work and found value in it. That's a real cost. The A1 path exists precisely because NIH recognizes that a scored application often has a credible shot at funding with focused revision. Skipping it without good reason is leaving something on the table.

A call with your program officer before you decide is almost never wasted. They can tell you whether the application's area fits current institute priorities, whether the assigned study section was an appropriate match, and sometimes — depending on how comfortable they are with you — what the informal funding landscape looks like for the next council round.

What A0 and A1 Actually Mean in NIH Terminology

In NIH grant language, the amendment number is appended to the application type: A0 for a first-time submission, A1 for the first resubmission. NIH eliminated the A2 option in 2009, after data suggested that third-try applications were consuming substantial review resources without producing proportionally better outcomes.

The important policy clarification — which NIH has made explicit in guidance over the years — is that a new A0 application can address the same broad scientific question as an earlier unfunded project, as long as it's genuinely redesigned rather than simply repackaged. The phrase NIH uses is "substantively different," and the key factors are whether the specific aims, the research strategy, and the central hypothesis have meaningfully changed. A renamed title with the same paragraphs rearranged does not qualify. A genuinely new set of aims that approaches the scientific question from a different angle, using different approaches or expanded preliminary data, typically does.

If there's any ambiguity about whether your revision qualifies as substantively different, ask your program officer before you submit. NIH staff can assess this before the application arrives, which saves you the problem of a reclassification after submission.

The Case for A1: When Resubmitting Makes Sense

A resubmission works best when the critiques are specific and correctable. This means reviewers pointed to concrete gaps — a missing control arm, an absent co-investigator with a key expertise, insufficient preliminary data for one aim — that you can genuinely address before the next cycle. Specific critiques give you a roadmap. The Introduction page lets you show reviewers exactly where and how you responded, which is a format they understand and that assigned reviewers will return to at the discussion meeting.

Score proximity matters too. If your application discussed at study section and received a percentile score close to the institute's historical payline — and you know roughly what that range looks like from public data or a PO conversation — the assigned reviewers already consider your science fundable at some level. Abandoning that for an A0 means rebuilding reviewer familiarity from scratch. In a strong A1, those same or similar reviewers may come in as your advocates.

Timeline pressure can also favor an A1. If you're approaching the end of a K Award, a training period, or a situation where independent funding has a hard deadline, the faster path matters. An A1 can typically be submitted in the next standard cycle, whereas a genuinely redesigned A0 may need additional time to develop new preliminary data that justifies the new framing.

The Case for A0: When Starting Fresh Wins

A new application wins when the critiques are structural rather than specific. If reviewers' central concern is that the hypothesis is too incremental, that the field has already addressed the question from a different angle, or that the aims don't cohere as a five-year program — those are framing problems. An Introduction page responding to them rarely shifts the score because you're not changing the thing reviewers objected to; you're explaining why they were wrong to object to it. That rarely works.

A new A0 also makes sense when the science has moved since your last submission. If a competing group published key findings that either support or complicate your central hypothesis, if a new technique became available that changes how you'd approach Aim 2, or if your own preliminary data shifted your working model — a fresh application lets you reframe around the current landscape without being constrained by what you committed to in the prior version.

Sometimes the study section assignment itself is the problem. If your summary statement suggests the assigned panel had a fundamental theoretical disagreement with your approach — one that isn't resolvable through better methods or more data — a new A0 gives you the chance to request a different study section through your cover letter. An A1 goes back to the same panel.

Reading Your Summary Statement to Make the Call

Most investigators read their summary statement looking for what to fix. Try reading it first looking for what the decision should be. Four things are worth isolating before you decide anything.

First, classify each critique as specific or general. "Aim 2 lacks adequate controls for off-target binding" is specific. "The approach does not adequately justify the proposed timeline" is general. A summary statement full of specific critiques almost always favors an A1. One full of general concerns — especially across multiple reviewers — usually doesn't.

Second, count how many distinct concerns are raised across all three reviewers. Three reviewers who each raised one different tractable concern is actually a good A1 candidate: three specific problems, three clear responses. Three reviewers who all circled the same fundamental concern from different directions — "lacks innovation," "question largely addressed," "incremental relative to published work" — is a signal that revision won't reach far enough.

Third, look at the Significance criterion score in isolation. If Significance is a 4 or worse, the panel didn't find the question important enough. This is almost never fixed by a better Approach section. You either need to reframe the significance argument substantially — which usually means a redesigned A0 — or reconsider whether the application fits this institute's current portfolio.

Fourth, look at what reviewers said about preliminary data. "Preliminary data are insufficient to support the feasibility of Aim 3" is a common critique, and it can go either way. If you can generate that data before the next cycle, an A1 is appropriate. If you can't, submitting an A1 without the requested evidence is a known failure mode. Reviewers remember what they asked for, and seeing it missing in the revision often hardens rather than softens a critique.

Timing the Decision Right

NIH's standard submission cycles fall roughly in February, June, and October for most research grant mechanisms, though this varies by opportunity and institute. After you receive your score, you don't need to submit in the very next cycle. Taking two or three cycles to develop genuine preliminary data and write a more considered response often outperforms a rushed A1 submitted four months after the original score. Reviewers can tell the difference.

One logistical point worth knowing: for most standard research applications, you have up to 37 months from the original A0 receipt date to submit an A1 and still have it treated as a resubmission. After that window, the application must be submitted as a new A0 regardless of how similar it is. If you're close to that window, confirm the specific deadline with your grants administrator or program officer — the exact rule varies by mechanism.

If you're considering a new A0, give yourself enough time to genuinely redesign. An application that keeps 80 or 90 percent of the prior text with reshuffled sections risks reclassification as a resubmission at the NIH end, which creates administrative delays and can leave the application in a holding pattern. Build the new A0 from the aims outward, not from the prior text downward.

Pay attention to institute priority signals when you time either path. A Notice of Special Interest (NOSI) aligned with your work, or a direct comment from your program officer that a particular topic is currently in focus for the next council round, can shift the value of getting an application in front of that council now rather than waiting for a more polished submission two cycles later. There isn't always a right answer, but the institute's current priority state is a real variable in the calculation.

Frequently Asked Questions